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Summary 
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, 
VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), 
assessed the risk of "other substances" in food supplements and energy drinks sold in 
Norway. VKM has assessed the risk of doses given by NFSA. These risk assessments will 
provide NFSA with the scientific basis while regulating "other substances" in food 
supplements. 
"Other substances" are described in the food supplement directive 2002/46/EC as substances 
other than vitamins or minerals that have a nutritional and/or physiological effect. It is added 
mainly to food supplements, but also to energy drinks and other foods. In this series of risk 
assessments of "other substances" the VKM has not evaluated any claimed beneficial effects 
from these substances, only possible adverse effects. 
The present report is a risk assessment of specified doses of L-threonine in food 
supplements, and it is based on previous risk assessments and articles retrieved from 
literature searches. 
According to information from NFSA, L-threonine is an ingredient in food supplements sold in 
Norway. NSFA has requested a risk assessment of 1000, 1200, 1500, 2000 and 2400 mg/day 
of L-threonine from food supplements.  
L-threonine is an essential amino acid not known to cause any adverse health effects. 
Previous reports do not indicate a tolerable upper intake level, apart from an approval of a 
dose of 1150 mg/day by the Scientific Committee of the Spanish Agency for Food Safety and 
Nutrition (AESAN). Long-term studies in humans were not found. The only available human 
studies were: a small uncontrolled one-year pilot study with doses ranging from 0.5 to 2.5 
g/day, one eight-week randomised controlled trial (RCT) using a dose of 7.5 g/day, and two 
2-week RCTs using doses of 6 and 4.5 g/day. No adverse effects (diary method of 
registration of adverse effects) were reported in the eight-week clinical trial, and the only 
adverse effects observed in the two-week trials were one case of indigestion and one case of 
diarrhoea. A four-week rodent toxicity study indicated a no observed adverse effect level 
(NOAEL) of 854.3 mg/kg bw per day (only dose tested, no adverse effects observed).  
The value used for comparison with the estimated exposure in the risk characterisation is the 
NOAEL defined in an 8-week randomised placebo controlled study in humans, 7500 mg/day. 
For a 70-kg individual, this corresponds to 107 mg/kg bw per day. Two human two-week 
studies and a small one-year pilot study support the notion that this dose will be well 
tolerated. The overall mean threonine intake according to NHANES III (3 g/day) is slightly 
larger than the doses requested for evaluation in the present risk assessment. 
No studies in children (10 to <14 years) and adolescents (14 to <18 years) were identified. 
Based on the included literature there was no evidence indicating that age affects the 
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tolerance for relevant doses of threonine. Therefore, in this risk characterisation a tolerance 
as for adults, based on body weight, was assumed for these age groups. 
VKM concludes that: 
 In adults (≥18 years), the specified doses 1000, 1200, 1500, 2000 and 2400 mg/day 
L-threonine in food supplements are unlikely to cause adverse health effects.  
 In adolescents (14 to <18 years), the specified doses 1000, 1200, 1500, 2000 and 
2400 mg/day L-threonine in food supplements are unlikely to cause adverse health 
effects.  
 In children (10 to <14 years), the specified doses 1000, 1200, 1500, 2000 and 
2400 mg/day L-threonine in food supplements are unlikely to cause adverse health 
effects.  
Children younger than 10 years were not within the scope of the present risk assessment. 
Short summary  
At the request of the Norwegian Food Safety Authority, the Norwegian Scientific Committee 
for Food Safety (VKM) has characterised the risk of specified doses of L-threonine in food 
supplements. VKM concludes that: 
 In adults (≥18 years), the specified doses 1000, 1200, 1500, 2000 and 2400 mg/day 
L-threonine in food supplements are unlikely to cause adverse health effects.  
 In adolescents (14 to <18 years), the specified doses 1000, 1200, 1500, 2000 and 
2400 mg/day L-threonine in food supplements are unlikely to cause adverse health 
effects.  
 In children (10 to <14 years), the specified doses 1000, 1200, 1500, 2000 and 
2400 mg/day L-threonine in food supplements are unlikely to cause adverse health 
effects. 
Key words: Threonine, food supplement, adverse health effect, negative health effect, 
Norwegian Food Safety Authority, Norwegian Scientific Committee for Food Safety, other 
substances, risk assessment, VKM 
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Sammendrag på norsk 
På oppdrag for Mattilsynet har Vitenskapskomiteen for mattrygghet (VKM) vurdert risiko ved 
tilsetting av "andre stoffer" i kosttilskudd og energidrikk som selges i Norge. VKM har 
risikovurdert ulike bruksdoser oppgitt fra Mattilsynet. Disse risikovurderingene vil gi 
Mattilsynet vitenskapelig grunnlag for å regulere "andre stoffer" i kosttilskudd. 
"Andre stoffer" er beskrevet i kosttilskuddirektivet (2002/46/EF) som stoffer som har en 
ernæringsmessig eller fysiologisk effekt, og som ikke er vitaminer og mineraler. De tilsettes i 
hovedsak til kosttilskudd, men også til energidrikker og andre næringsmidler. I disse 
risikovurderingene har VKM ikke vurdert potensielle gunstige helseeffekter, men kun vurdert 
mulige negative helseeffekter. 
I denne rapporten har VKM vurdert helserisiko ved L-treonin som kosttilskudd. Vurderingen 
er basert på andre tidligere risikovurderinger av aminosyren og vitenskapelige artikler som er 
funnet i systematiske litteratursøk.  
Ifølge informasjon fra Mattilsynet er L-treonin en ingrediens i kosttilskudd som selges i 
Norge. Oppdraget fra Mattilsynet var å risikovurdere følgende doser av L-treonin i 
kosttilskudd: 1000, 1200, 1500, 2000 og 2400 mg/dag.  
L- treonin er en essensiell aminosyre uten kjente negative helseeffekter. Tidligere rapporter 
støtter oppfatningen av at treonin har lav toksisitet, men angir ikke et øvre tolerabelt 
inntaksnivå  bortsett fra at de spanske vitenskapskomiteen for mattrygghet og ernæring 
(AESAN) har godkjent en dose på 1150 mg/dag. Det er kun funnet fire humanstudier; en 
liten ukontrollert pilotstudie med ett års varighet og doser fra 0,5 til 2,5 g/dag, en 8-ukers 
randomisert, placebokontrollert studie med en dose på 7,5 g/dag, og to randomiserte 
placebokontrollerte studier av 2 ukers varighet med doser på 6 og 4,5 g/dag. Det ble ikke 
rapportert om negative helseeffekter (dagbok-metode for registrering) i den kliniske 8-ukers 
studien, og de eneste rapporterte negative helseeffekter i 2-ukersstudiene var ett tilfelle av 
fordøyelsesproblemer og ett tilfelle med diaré. I en 4 uker lang toksisitetsstudie i gnagere ble 
det indikert en NOAEL (no observed adverse effect level) på 854,3 mg/kg kroppsvekt per 
dag (eneste dose testet). 
Som basis for vår sammenligningsverdi ("value of comparison») valgte vi å benytte 
7500 mg/dag fra den åtte uker lange randomiserte, placebokontrollerte studien i mennesker. 
Dette svarer til 107 mg/kg kroppsvekt per dag hos en person på 70 kg. To 2-ukers 
humanstudier og en liten pilotstudie i mennesker støtter opp under vurderingen av at en slik 
dose vil bli godt tolerert. 
Gjennomsnittlig inntak av treonin (3 g/dag i følge data fra NHANES III, USA) er litt større 
enn de dosene VKM er bedt om å vurdere for kosttilskudd.  
Det ble ikke avdekket noen studier med barn (10 til <14 år) eller ungdom (14 til <18 år). 
Det er imidlertid ingen indikasjoner på at alder påvirker toleransen for treonin i de inkluderte 
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studiene. I denne risikovurderingen er det derfor antatt at barn og ungdom har samme 
toleranse, per kroppsvekt, som voksne. Vitenskapskomiteen for mattrygghet (VKM) 
konkluderer med at: 
 For voksne (≥18 år) er det usannsynlig at de spesifiserte dosene på 1000, 1200, 
1500, 2000 and 2400 mg/dag L-treonin i kosttilskudd vil forårsake negative 
helseeffekter. 
 For ungdom (14 til <18 år) er det usannsynlig at de spesifiserte dosene 1000, 1200, 
1500, 2000 and 2400 mg/dag L-treonin i kosttilskudd vil forårsake negative 
helseeffekter. 
 For barn (10 til <14 år) er det usannsynlig at de spesifiserte dosene på 1000, 1200, 
1500, 2000 and 2400 mg/dag L-treonin i kosttilskudd vil forårsake negative 
helseeffekter. 
Barn under 10 år inngår ikke i dette oppdraget. 
Kort sammendrag  
Vitenskapskomiteen for mattrygghet (VKM) har på oppdrag for Mattilsynet vurdert risiko ved 
inntak spesifikke doser av L-treonin i kosttilskudd. VKM konkluderer med at: 
 For voksne (≥18 år) er det usannsynlig at de spesifiserte dosene på 1000, 1200, 
1500, 2000 and 2400 mg/dag L-treonin i kosttilskudd vil forårsake negative 
helseeffekter. 
 For ungdom (14 til <18 år) er det usannsynlig at de spesifiserte dosene på 1000, 
1200, 1500, 2000 and 2400 mg/dag L-treonin i kosttilskudd vil forårsake negative 
helseeffekter. 
 For barn (10 til <14 år) er det usannsynlig at de spesifiserte dosene på 1000, 1200, 
1500, 2000 and 2400 mg/dag L-treonin i kosttilskudd vil forårsake negative 
helseeffekter. 
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Abbreviations and glossary 
Abbreviations 
AESAN  - Spanish Agency for Food Safety and Nutrition 
ASC  - alanine/serine/systeine 
ASCT  - alanine/serine/cysteine transporter 
ATA  - amino acid transporter 
bw  - body weight 
CoA  - coenzym A 
EAT  - excitatory amino acid-Na+ cotransporter 
EFSA  - European Food Safety Authority 
EMBASE - a database that registrerers references from articles in more than 7600 
  medical journals from different countries, with a particular coverage of  
  Western European publications 
IOM  - Institute of Medicine, USA 
LAT  - system L neutral amino acid transporter (LAT; LAT1, LAT2, LAT3, or LAT4) 
LOAEL  - lowest observed adverse effect level 
MEDLINE - the U.S. National Library of Medicine® (NLM) premier bibliographic database 
  that contains more than 23 million references to journal articles in life sciences 
  with a concentration on biomedicine 
MOE  - margin of exposure 
NFSA  - Norwegian Food Safety Authority [Norw.: Mattilsynet] 
NHANES - National Health and Nutrition Examination Survey, USA 
NOAEL  - no observed adverse effect level 
OECD  - Organisation for Economic Co-operation and Development 
PepT  - peptide transporter 
RCT  - randomised controlled trial 
SLC15A - Solute Carrier 15 (SLC15) family of peptide transporters is a group of  
  membrane transporters including SLC15A1 (PEPT1) and SLC15A2 (PEPT2)
  SMA15 - Sequential Multiple Analysis 15 - a clinical chemistry test battery 
UL  - tolerable upper intake level 
VKM  - Norwegian Scientific Committee for Food Safety [Norw.: Vitenskapskomiteen 
for Mattrygghet] 
WHO  - World Health Organization 
Glossary 
"Other substances": a substance other than a vitamin or mineral that has a nutritional or 
physiological effect (European Regulation (EC) No. 1925/2006, Article 2; http://eur-
lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32006R1925&from=en).  
"Negative health effect" and "adverse health effect" are broad terms. The World Helath 
Organization (WHO) has established the following definition of "adverse effect": a change in 
morphology, physiology, growth, development, reproduction or life span of an organism, 
system or (sub)population that results in an impairment of functional capacity, an 
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impairment of the capacity to compensate for additional stress, or an increase in 
susceptibility to other influences (WHO, 1994). 
An adverse event is considered serious if it results in death, is life-threatening, requires or 
prolongs hospitalisation, is a congenital anomaly or birth defect, is a persistent or significant 
disability/incapacity, or is another serious or important medical event. 
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Background as provided by the 
Norwegian Food Safety Authority 
"Other substances" are substances other than vitamins and minerals, with a nutritional 
and/or physiological effect on the body. "Other substances" are mainly added to food 
supplements, but these may also be added to other foods and beverages, such as sports 
products and energy drinks. Ingestion of these substances in high amounts presents a 
potential risk for consumers. 
In Norway, a former practice of classification of medicines had constituted an effective 
barrier against the sale of potentially harmful "other substances". Ever since this practice 
was changed in 2009, it has become challenging to regulate and supervise foods with added 
"other substances". Meanwhile, in the recent years, the Norwegian market has witnessed a 
marked growth in the sales of products containing "other substances". In 2011, food 
supplements containing "other substances" constituted more than 50% of the market share. 
While within the European Economic Area, these substances fall under the scope of the 
European Regulation (EC) No. 1925/2006 on the addition of vitamins, minerals and certain 
other substances to foods and the European Regulation (EC) No 258/97 concerning novel 
foods and novel food ingredients, "other substances" remain largely unregulated. In order to 
ensure safe use of "other substances" many countries have regulated their use at a national 
level. For example, Denmark regulates these substances in a positive list i.e. a list of 
substances with maximal daily doses, permitted for use in food supplements and other foods 
(FVM, 2014).  
The Norwegian Food Safety Authority (NFSA) is working on the establishment of a regulation 
on the addition of "other substances" to foods at a national level. The regulation will include 
a list of substances with permitted maximal doses, based on the substances and doses found 
in products on the Norwegian market. In preparation for a regulation, NFSA has therefore 
requested the Norwegian Scientific Committee for Food Safety (VKM) to assess the safety of 
"other substances" found on the Norwegian market. NFSA, in consultation with the industry, 
has compiled a list of "other substances" found in products marketed in Norway. Only 
substances with a purity of minimum 50% or concentrated 40 times or more have been 
included in the list. Substances regulated by other legislations like those for novel foods, 
food additives, aromas, foods for special medical purposes, etc. have been excluded from 
the list.  
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Terms of reference as provided by the 
Norwegian Food Safety Authority 
The Norwegian Food Safety Authority (NFSA) requested the Norwegian Scientific Committee 
for Food Safety (VKM) to assess the safety of L-threonine in food supplements at the 
following doses: 1000, 1200, 1500, 2000 and 2400 mg/day. 
NFSA requested VKM to assess the safety of "other substances" (in accordance with the 
guidance document developed in Phase 2) for the specified doses (Phase 3). 
The safety assessments for "other substances" present in food supplements shall be carried 
out for the general population, age 10 years and older.  
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1 Introduction 
"Other substances" are described in the food supplement directive 2002/46/EC as substances 
other than vitamins or minerals that have a nutritional and/or physiological effect, and may 
be added to food supplements or e.g. energy drinks.  
This risk assessment regards the substance L-threonine per se, and no specific products. 
In this series of risk assessments of "other substances" the VKM has not evaluated any 
claimed beneficial effects from these substances, but merely possible adverse effects at 
specified doses used in Norway.  
According to information from the Norwegian Food Safety Authority (NFSA), L-threonine is 
an ingredient in food supplements sold in Norway. NFSA has requested a risk assessment of 
the intake of 1000, 1200, 1500, 2000 and 2400 mg L-threonine per day from food 
supplements. The total threonine exposure from other sources than food supplements is not 
included in the risk assessment. 
L- threonine is an essential/indispensable, neutral amino acid. Threonine is needed for the 
synthesis of proteins, and practically all human proteins and peptides contain threonine.  
In humans threonine is mainly catabolised by threonine dehydratase to NH3 and 2-
ketobutyrate and further downstream to propionyl-CoA, which is rapidly and irreversibly 
converted to CO2 in the Krebs cycle. An alternative, minor pathway (<10%) is initiated by 
threonine dehydrogenase before cleavage to form glycine and acetyl-CoA. By this latter 
pathway threonine will supply substrates for both the glucose and lipid synthesis (Darling et 
al., 2000). 
All protein sources contain threonine. Based on the threonine content of soy protein, a 
protein intake of 100 g/day is estimated to provide about 4 g of L-threonine. According to 
the third National Health and Nutrition Examination Survey (NHANES III, 1988-1994), the 
overall mean intake of L-threonine from food and food supplements in the United States was 
3 g/day. Recommended daily intake is 15 mg/kg bw per day (WHO, 2007), corresponding to 
1050 mg for a 70-kg person. Adequate amounts of threonine will be consumed when total 
protein intake meets recommendations. 
  
  
VKM Report 2017: 10  15 
2 Hazard identification and 
characterisation 
2.1 Literature 
This risk assessment is based on previous risk assessments of L-threonine, as well as 
scientific papers retrieved from systematic literature searches. The literature searches aimed 
at retrieving human as well as animal studies on adverse effects caused by L-threonine.  
 Previous risk assessments 
Risks related to L-threonine have previously been evaluated by the Institute of Medicine 
(IOM) in USA in 2005, EFSA in 2006 and 2008, VKM in 2011 and the Scientific Committee of 
the Spanish Agency for Food Safety and Nutrition (AESAN) for use in food supplements in 
2012 (AESAN, 2012; IOM, 2005; VKM, 2011). 
Table 2.1.1-1: Overview of previous risk assessments of L-threonine. 
Risk 
assessment 
body, country, 
publication 
year 
Objective Conclusion Suggested doses 
 
IOM, USA 2005 To establish dietary reference 
intakes for L-threonine, and other 
nutrients. Includes a discussion of 
potential toxicity. 
L-threonine: the data on possible adverse 
effects of L-threonine intake from 
supplements were not available for a dose–
response assessment and derivation of a UL 
in apparently healthy humans 
L-threonine: Not 
established 
EFSA, 2006 To evaluate the safety of a group 
of flavouring agents, including L-
threonine. 
The available data on threonine do not give 
rise to safety concern with respect to 
genotoxicity. 
L-threonine: 
Not established 
 
EFSA, 2008 To evaluate the safety of a group 
of flavouring agents, including L-
threonine. 
Threonine [FL-no: 17.021] would not give 
rise to safety concerns at the estimated 
levels of intake arising from its use as a 
flavouring substance. Threonine is expected 
to be metabolised to innocuous products.  
L-threonine: 
Not established  
 
VKM, Norway, 
2011 
To qualitatively rank 30 amino 
acids according to high, medium 
or low risk  
Threonine was grouped as "moderate risk"  Threonine: 
Not established 
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Risk 
assessment 
body, country, 
publication 
year 
Objective Conclusion Suggested doses 
 
AESAN, Spain, 
2012 
The use of threonine as a food 
supplement was assessed 
The AESAN report largely builds on the IOM 
2005 report, and finds the proposed dose 
acceptable from a safety viewpoint without 
citing specific considerations. Additionally, 
the proposed dose is in line with the daily 
requirement of L-threonine established by 
WHO. 
L-threonine 
1150 mg/day 
acceptable 
Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty 
Acids, Cholesterol, Protein, and Amino Acids from Institute of Medicine 
(IOM). USA, 2005 
A study in which rats fed 5 percent threonine added to a 10 percent casein diet, showed 
reduced weight gain, but no changes in liver weight, hepatic DNA, RNA, or protein content 
compared to controls fed casein alone (Muramatsu et al., 1971). In weanling pigs, adding 
0.5, 1, 2, or 4% L-threonine to a 20% crude protein diet did not change weight gain, food 
intake, and gain: feed ratios in comparison to the controls (Edmonds and Baker, 1987; 
Edmonds et al., 1987). Evidence indicates that excess threonine is converted to 
carbohydrate, liver lipids, and carbon dioxide (Yamashita and Ashida, 1971). 
No data were found by IOM on apparently healthy humans given oral L-threonine 
supplements. L-threonine has also been used clinically with the aim of increasing glycine 
concentrations in the cerebro-spinal fluid of patients to reduce spasticity. When given in 
amounts of 4.5 to 6.0 g/day for 14 days, no adverse clinical effects were noted in such 
patients (Growdon et al., 1991).  
IOM (2005) found that the data on possible adverse effects of L-threonine intake from 
supplements were not available for a dose–response assessment and derivation of a 
tolerable upper intake level (UL) in apparently healthy humans.  
EFSA, 2006 and 2008 
The available data on threonine do not give rise to safety concerns with respect to 
genotoxicity. Threonine is expected to be metabolised to innocuous products (EFSA, 2006; 
EFSA, 2008). 
VKM report on risk categorisation of amino acids. Norway, 2011 
In 2011, VKM conducted a risk categorisation of about 30 amino acids and amino acid 
compounds based on potential health risks related to high intakes of the amino acids (VKM, 
2011). Amino acids were to be grouped into one of three categories, high risk, moderate 
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risk, and low risk. It was emphasised that the VKM report from 2011 has several limitations 
and can only be regarded as an initial screening and not as a risk assessment of the many 
amino acids. 
In the absence of human studies on negative health effects, threonine was placed in the 
group ‘moderate risk’. The justification was that there is little documentation regarding 
health effects of threonine, and that amino acids in general are bioactive components.  
Report of the Scientific Committee of the Spanish Agency for Food Safety 
and Nutrition (AESAN) on the use conditions for certain substances other 
than vitamins, minerals and plants in food supplements - 1. Spain, 2012 
The AESAN report largely cites the IOM (2005) evaluation (AESAN, 2012). A proposal of a 
maximum dose of 1150 mg/day for use as a food supplement was found acceptable from the 
safety viewpoint, also because it is in line with the daily requirement of L-threonine 
established by WHO (2007). 
 Literature search 
Literature searches were performed in MEDLINE and EMBASE in order to retrieve 
publications on adverse effects caused by L-threonine. Both databases were searched to 
ensure comprehensive study retrieval. The literature search was conducted 5 April 2016, and 
included human studies in general. Since studies in children and adolescents were lacking, 
an additional literature search for these groups was performed 13 October. Further, a 
literature search for relevant animal studies was performed 16 September 2016.  
The strategies for the searches are outlined in Appendix 1. 
2.1.2.1 Publication selection and data extraction 
The literature search for human studies identified 427 articles, and the search for studies in 
children and adolescents 17 studies. The search for animal studies identified 440 titles. In 
the primary screening, titles and abstracts of all unique publications retrieved were 
independently screened against the inclusion criteria.  
Inclusion criteria: 
 An adverse effect/adverse effects in relation to threonine alone is addressed 
 Route of exposure for humans is oral 
 Route of exposure for animals is oral, in addition, subcutaneous exposure is included 
if the toxicokinetics are equal as by oral exposure 
 Human studies are performed in apparently healthy individuals or patient groups 
assumed to have normal threonine absorption and metabolism 
 Animal model studies address adverse effects relevant to human health 
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In vitro studies were not included, but relevant titles were read in order to find background 
information regarding potential toxic properties of L-threonine. 
Data from studies on acetyl-threonine were used only as supportive information. 
The inclusion criteria checklist was developed by members of the Panel on Food Additives, 
Flavourings, Processing Aids, Materials in Contact with Food and Cosmetics and the Panel on 
Nutrition, Dietetic Products, Novel Food and Allergy. Titles and abstracts that did not fulfil 
the inclusion criteria were excluded from further screening. In situations where it was 
unclear whether the publication was of relevance to the current risk assessment, it was 
retained for further screening. The primary screening was performed independently by two 
persons.  
The papers that passed the primary screening were reviewed in full against the same 
inclusion criteria by the author author of this report. 
For the general human studies search, the first screening resulted in 3 full text articles, all 
included after full text reading, with the addition of one paper found by hand search. From 
the search for studies in children and adolescents, no studies were included after the first 
screening. One animal study was included after the first screening and full text reading (see 
Figure 2.1.2.1-1). 
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Figure 2.1.2.1-1: Flowchart for publication selection for L-threonine. 
2.2 General information 
 Chemistry 
L- threonine, also named (2S,3R)-2-amino-3-hydroxybutyric acid, is an indispensable 
(essential), neutral amino acid. The molecular formula is C4H9NO3. The CAS number for L-
threonine is 72-19-5. The structural formula is shown in figure 2.2.1-1. 
 
Figure 2.2.1-1: Structural formula of L-threonine. 
Searches for human studies, animal studies and specific 
studies in children and adolescents 
The publications were identified searching Embase, 
Global Health, Medline and Web of Science 
Titles and abstracts 
Human n = 427 
Children/adolescents n=17 
Animal n=440 
 
Full text 
Human n = 3 
Animal n=1 
 Manual search 
1 publication 
(human) was 
identified 
Publications not fulfilling the 
inclusion criteria were excluded 
n = 0 
Publications not fulfilling the 
inclusion criteria were excluded 
Human n = 424 
Children/adolescents n=17 
Animal n=439 
5 publications 
included 
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 Occurrence 
All protein sources contain threonine. Animal and bean proteins have a slightly higher 
content (4-5% of total protein) than grain proteins (3-4% of total protein). Adequate 
amounts of threonine will be consumed when total protein intake meets recommendations, 
actually the threonine requirements (1050 mg/day for a 70 kg person, according to the WHO 
(2007) recommendation of 15 mg/kg bw per day) are certain to be exceeded several-fold. 
2.3 Absorption, distribution, metabolism and excretion 
 In humans 
Absorption 
Free threonine from digested proteins is taken up from the small intestinal lumen by the 
sodium-amino acid cotransport systems Bo and ASC (Avissar et al., 2001; Munck and Munck, 
1999). Threonine as a component of di-and tripeptides can also be taken up via hydrogen 
ion/peptide cotransporter 1 (SLC15A1, PepT1) and, to a lesser extent, hydrogen 
ion/peptide cotransporter 2 (SLC15A2, PepT2).  
Export across the enterocyte basolateral membrane uses the sodium-amino acid cotransport 
systems A (ATA2) and ASC (ASCT1), and possibly other systems. As long as the amino acid 
concentration is higher inside the cell than in the basolateral space, transport can occur 
against the considerable sodium gradient. When the intracellular amino acid concentration 
falls below extracellular levels during fasting, transport turns towards the enterocyte and 
supplies needed amino acids.  
Both the brush border membrane and the enterocyte basolateral membrane contain 
transporters that exchange amino acids. Neutral amino acids that are enriched in the cell by 
the sodium cotransporters are exchanged for a wide spectrum of other amino acids.  
Metabolism  
Threonine is needed for the synthesis of proteins, and practically all human proteins and 
peptides contain threonine. The metabolic pathway of L-threonine is closely linked to 
those of glycine and L-serine. L-threonine is not a substrate in transamination reactions. 
Threonine is mainly catabolised by threonine dehydratase to NH3 and 2-ketobutyrate and 
further downstream to propionyl-CoA, which is rapidly and irreversibly converted to CO2 in 
the Krebs cycle. An alternative, minor pathway (<10%) is catalysed initially by the enzyme 
threonine dehydrogenase before cleavage to form glycine and acetyl-CoA. By this latter 
pathway threonine will supply substrates for both the glucose and lipid synthesis (Darling et 
al., 2000). In energy terms, threonine yields 3.4 kcal/g. 
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Transport, cellular uptake and storage 
Plasma concentration of threonine is about 130 µmol/l. It is lowest during the early morning 
hours and increases significantly after meals. Human studies have shown that threonine 
treatment has increased blood and cerebrospinal fluid levels of threonine but not  of glycine  
(Hauser et al., 1992; Tsai and Huang, 1999). Uptake from the blood into tissues occurs via 
an array of transporters, many of them identical or similar to those mediating intestinal 
absorption. However, expression patterns are reported to vary greatly between different cell 
types.  
The rise in cerebrospinal fluid threonine levels with treatment is in line with animal data 
indicating passage of this amino acid across the blood-brain barrier, but the specific roles of 
the different transport systems are not yet well understood. 
Regarding feto-maternal transport, threonine is taken up from the blood across the brush 
border membrane of the syncytiotrophoblast by the sodium-amino acid cotransport system A 
(possibly also ASC and N), and the sodium-independent system L. Transfer across the 
basolateral membrane proceeds via the sodium-amino acid cotransport system A and the 
sodium-independent transporters EAT1 and LAT2. 
Assuming an average threonine content of human proteins of 48 mg/g, a 70-kg man may 
have a mobilisable reserve of about 300 g. 
Excretion  
In the kidneys, free threonine filtered in the glomeruli is reabsorbed into the proximal renal 
tubuli by sodium-amino acid cotransport systems Bo and ASC. Dipeptides and tripeptides are 
taken up by via PepT1 and PepT2. The renal recovery of threonine is nearly complete in 
healthy prople. In normal gastrointestinal function, losses via faeces also are negligible. Most 
nitrogen from metabolised threonine is excreted into urine as urea. Minor metabolic products 
are aminoacetone and D-lactate, and the urinary excretion of these increases disprotionally 
with high threonine intake and in situations with low availability of free CoA. 
2.4 Toxicological data/Adverse effects 
 Human studies 
For the general human studies search, the first screening resulted in 3 full text articles, all 
included after full text reading, with the addition of one paper found by hand search. The 
search for studies in children and adolescents gave no titles that could be included after the 
first screening. 
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Table 2.4.1-1 An overview of human studies investigating adverse health effects of threonine 
supplementation. 
Reference Study design/ 
participant 
characteristics 
Country  Number in 
treatment group 
Dose Main 
endpoint 
Length of 
intervention 
Adverse 
effects 
(verum groups) Active Control 
RCTs 
(all with 
crossover 
design) 
        
Lee & Paterson 
1993 
Spinal spasticity 
patients, 33 
patients (19 men 
and 14 women) 17 
to 70 years 
Northern 
Ireland 
33 33 6 g/d Spasticity 2 weeks 1 indigestion 
(moderate) 
1 diarrhoea 
(moderate) 
Hauser et al., 
1992 
Multiple sclerosis, 
26 patients (11 
men and 15 
women), 41±6.5 
years 
(mean±SEM) 
USA 26 26 7.5 g/d 
 
Spasticity  8 weeks None (by diary) 
Growdon et al., 
1991 
Familiar spastic 
paraparesis, 18 
patients (14 male, 
4 female) 23 – 70 
years 
USA 18 
 
18 4.5 g/d  
(n= 8) 
6 g/d  
(n=10)  
Spasticity 2 weeks None 
Open, 
uncontrolled 
        
Barbeau et al., 
1982 
Genetic spasticity 
syndromes, 6 
patients (4 
women, 2 men), 
mean age 29.7 
years 
Canada 6 None 500 mg/d 
or more (up 
to 2.5 g/d) 
Spasticity 1 year + 4 
months 
observation 
Dizziness (n=2) 
Nausea (n=3) 
Lee and Paterson, 1993 (Northern Ireland) 
A double-blind, placebo-controlled, cross-over, add-on design study of oral L-threonine at 
6 g/day with 2-week treatment periods was performed in 33 patients with spinal spasticity 
(14 women, 19 men; age from 17 to 70 years) (Lee and Patterson, 1993). Multiple sclerosis 
was the diagnosis in 26 patients, spinal cord injury in five, syringomyelia in one, and spinal 
tumour in one. Fourteen patients were on no antispastic therapy during the trial, 12 were on 
baclofen alone, and 7 on a combination of baclofen and either dantrolene or diazepam. 
Patients were recruited from neurology and spinal injury clinics and from hospital wards for 
the young disabled. 
There were four study periods: 1) four-week baseline, 2) two-week treatment period, 3) 
two-week washout, and 4) two-week treatment period. L-threonine 6 g/day was given as 
500 mg capsules three times daily on an empty stomach; placebo capsules had the same 
appearance and taste. Treatment randomisation was carried out by a medical statistician and 
the codes were held by the hospital pharmacy. Blocks of six were used in the random 
number generation. Patients’ and caregivers’ opinions on improvement were recorded and 
any side effect documented. 
There was a strong rise in plasma threonine levels during therapy. Four patients who started 
the study failed to complete it because of intercurrent infections (n=2) or non-medical 
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reasons (n=2). Two patients on L-threonine treatment reported minor side-effects which did 
not prevent them from completing the study: indigestion and diarrhoea were each reported 
once. One patient complained on headaches on placebo treatment. 
Hauser et al., 1992 (USA) 
Twenty-six patients (15 females, 11 men; mean (±SEM) age 41±6.5 years) with clinically 
definite multiple sclerosis were enrolled in this double blind, placebo-controlled cross-over 
study (Hauser et al., 1992). Ambulatory patients with inactive or very slowly progressive 
multiple sclerosis were eligible (definitions of ‘inactive’ and ‘very slowly progressive’ as well 
as inclusion and exclusion criteria are specified). Threonine was supplied as a purified amino 
acid in 500-mg capsules prepared by the hospital pharmacy. Active and placebo capsules 
(lactose) vere identical in appearance and taste. Group assignment was performed by the 
hospital pharmacist according to a prescheduled randomised computer-generated order of 
administration. The protocol consisted of two eight-week treatment periods separated by a 
two-week washout period. During each treatment period, the patients were asked to self-
administer five capsules three times daily, for a total daily dose of 7.5 g. Compliance was 
assessed by frequent patient contact, by return of empty capsule bottles, and by 
measurement of serum threonine levels. Before treatment, patients were instructed by a 
research dietitian to consume a standard 75-g protein diet, to be continued until completion 
of the study. Patients were asked to keep a diary form on which to record clinical symptoms 
of spasticity, as well as any side effects or illnesses they experienced. The treatment code 
was broken after all clinical and laboratory data had been entered into the database. 
Twenty-four patients completed at least one treatment period and 21 completed both 
treatment periods. Two patients dropped out during each treatment period for specified 
reasons, none because of treatment side effects. No side effects or toxic effects of threonine 
were identified.  
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Growdon et al., 1991 (USA) 
According to a double-blind, crossover protocol with 2-week intervention periods, L-threonine 
doses of 4.5 and 6.0 g/day were given to 18 patients (4 female, 14 male; age range 23 to 70 
years) with familial spastic paraparesis (Growdon et al., 1991). Threonine was given in 500 
mg capsules prepared by the institution’s research pharmacy; seven patients took 1.5 g 
three times daily (total 4.5 g/day) and nine patients took 2.0 g three times daily (total 6.0 
g/day); one patient took both doses and completed the study twice. Placebo capsules 
contained lactose and were identical to threonine capsules in appearance, texture and taste 
when intact. The response to treatment was evaluated at the end of each 2-week period. 
Blood specimens and cerebrospinal fluid samples were collected for each period. Plasma and 
cerebrospinal fluid threonine levels rose significantly during treatment.There were no 
noticeable clinical side effects of L-threonine administration (method of registration not 
indicated); the results of hematologic, hepatic and renal function tests did not change during 
treatment. 
Barbeau et al., 1982 (Canada) 
This is a one-year pilot study in which threonine supplementation (500 mg/day for most of 
the intervention period) was given to six patients (four women, two men; mean age 29.7 
years) with genetic spasticity syndromes for an overall period of 12 months, followed by a 
four month observation period without supplementation (Barbeau et al., 1982). Threonine 
was given in gelatine capsules of 250 mg. In detail, the protocol included an initial three-
week stay in the hospital metabolic unit, during which the threonine dose was increased 
gradually to tolerance, or to a maximum dose of 2.5 g/day. Upon discharge from the 
hospital, the dose of threonine was gradually decreased over the next two months to 500 
mg/day in most patients (range 500-1000 mg/day) and maintained at this dose for 9 
months. One year after intervention start threonine supplementation was stopped, and the 
patients were observed for a further four months without any treatment. 
Two patients experienced episodes of dizziness (“giddiness”) in the early phase of treatment, 
and three suffered from occasional nausea. No other symptoms could be associated with the 
treatment (method of registration not indicated). Hematological and clinical chemistry 
parameters (SMA-15) remained unchanged throughout the treatment. 
2.4.1.1 Interactions  
There was no information concerning interactions in the literature reviewed in the present 
risk assessment, apart from normal biochemical interactions during threonine metabolism. 
The absence of information in the selected literature does not document an absence of 
adverse interactions.  
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2.4.1.2 Allergic sensitisation (including adjuvant effects) 
There was no information concerning allergic sensitisation or allergy adjuvant effects in the 
literature reviewed in the present risk assessment. Threonine per se would not be expected 
to behave as an allergen. The absence of information in the selected literature does not 
document an absence of allergic sensitisation or allergy adjuvant effects. 
 Animal studies 
Of the titles identified in the search for animal studies, one study was included after the first 
screening and full text reading. This study is summarised in Table 2.4.2-1. 
Table 2.4.2-1: Overview of included animal studies investigating L-threonine in relation to adverse 
health effects, identified in the systematic literature search for animal studies. 
Reference Animals  Sub-
stance 
Doses Main 
endpoints 
Duration 
of 
exposure 
Adverse effects 
(verum group) 
NOAEL 
(mg/kg 
bw/day) 
van de 
Mortel et al. 
(2010) 
Sprague-
Dawley 
rats, 10 
rats per 
group per 
sex, 
randomised 
Threonine 
 
N-acetyl 
threonine  
Standard rodent 
diet, supple-mented 
to give 1000 mg/kg 
bw/day of 
threonine or 100, 
500, and 1000 
mg/kg bw/day of 
N-acetyl-threonine 
+ untreated control 
group 
OECD guide-
line 407 (plus 
muta-genicity 
and acute 
toxicity) 
4-week 
dietary 
study  
No biologically 
significant 
adverse effects 
neither for 
threonine nor for 
N-acetyl-
threonine 
M: 854.3 
F: 932.2 
 
Safety assessment of N-acetyl-L-threonine (van de Mortel et al., 2010) 
The purpose of this study was to investigate whether 4-week intake of a N-acetyl-L-
threonine supplemented diet would show any adverse effects in the Sprague-Dawley rat 
(both sexes) as determined according to the OECD Guideline 407 test protocol(van de Mortel 
et al., 2010). A group administered threonine 1000 mg/kg bw per day (dose aim) 
incorporated into a standard rodent diet was included as a control group in addition to 
untreated controls. All rats in the study survived until scheduled sacrifice, and no biologically 
significant differences from the normal controls were observed in any group for body weight, 
feed consumption, clinical signs, behavioural, ophthalmology, hematology, coagulation, 
clinical chemistry, organ weights or gross or microscopic changes. Consumed doses of 
threonine were 854.3 mg/kg bw per day for males and 932.2 mg/kg bw per day for females. 
Thus, the NOAEL for threonine demonstrated in this study can be considered to be the dose 
tested in males, 854.3 mg/kg bw per day. This finding is supported by the demonstration of 
a NOAEL of 848.5 mg/kg bw per day for N-acetyl-L-threonine which has been demonstrated 
to have a biological availability close to that of L-threonine (Boggs, 1978). 
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 In vitro studies 
The available data do not give rise to safety concern with respect to genotoxicity (EFSA, 
2006; van de Mortel et al., 2010). 
 Mode of action for adverse effects  
No specific or definite mechanisms for any potential adverse effects have been described. 
However, dietary threonine imbalance is known to reduce food intake and weight gain and 
the growth of the small intestine, liver, and skeletal muscle in young animals. Still, when 
added to low-protein diets, threonine causes less growth depression than other amino acids 
(Garlick, 2004). There were data suggesting increased muscle protein breakdown in weanling 
rats given diets containing excess amounts (0.5%-4%) of threonine (Sarwar et al., 1995). In 
a study by Wang et al. (2007) in a 25 day-old pig model, protein synthesis in skeletal muscle 
as well as jejunal mucosa and mucins was reduced to a greater extent than in the liver in 
response to an imbalance of dietary threonine (150% of recommended feed levels). These 
results suggest that an excess of dietary threonine decreases protein synthesis in rapidly 
growing tissues of young pigs. The findings provide an explanation for the lower growth 
performance of animals fed a threonine-imbalanced diet, although the specific underlying 
biochemical mechanism is largely unknown. 
 Vulnerable groups 
No vulnerable groups to excess doses of L-threonine have been reported, apart from 
suggestions from animal studies that excess threonine may reduce protein synthesis in 
rapidly growing tissues of very young animals. However, threonine has not been studied 
extensively but appears to be one of the least toxic of the amino acids (Garlick, 2004; Peng 
et al., 1973).  
There have been no reported studies involving children, elderly, pregnant women or 
lactating women.  
2.5 Summary of hazard identification and characterisation 
The information provided in previous risk assessment supports the notion that L-threonine 
has low, if any, toxicity, and no specific safety concerns have been raised. No studies, 
however were identified that provide data to support the determination of specific safe dose 
levels, apart from the AESAN (2012) approval of a dose of 1150 mg/day. 
For the risk evaluation of specified doses of L-threonine in food supplements, literature 
searches including both human and animal studies were performed. In these searches, we 
did not find any long-term studies in healthy individuals that could be used for safety 
evaluation. One small (n=6) uncontrolled pilot study of one year’s duration and three 
randomised crossover trials of eight, two, and two weeks duration, respectively, in 
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individuals suffering from muscular spasticity disorders of different ethiologies were 
identified. These studies were considered relevant for the present risk evaluation, because 
the disorders of the patients included in the studies are not likely to have significantly 
affected threonine absorption, distribution, and metabolism. Additionally, one four-week 
toxicity study in rats performed according to OECD guideline 407 was retrieved. 
In summary, the following information is considered in the current assessment: 
1. No long-term studies on L-threonine in healthy children, adolescents or adult humans 
were found. A small (n=6), open one-year pilot study in patients with spastic 
disorders treated with doses ranging from 0.5 to 2.5 g/day was found but can only 
serve as a supportive study.  
2. No adverse effects (diary method of registration) were reported in one randomised 
placebo controlled eight-week clinical trial with 7.5 g/day of threonine treatment. 
3. No adverse effects apart from one case of indigestion and one case of diarrhoea were 
observed in two randomised placebo controlled trials of two weeks’ duration (n=33, 
n=18) in which 6 g/day respective 4.5 g/day of L-threonine was given. 
4. In the literature, L-threonine is generally considered to be one of the amino acids 
with the least potential for toxicity, and produces innocuous metabolites.  
5. There are some indications from animal studies that excess doses of threonine may 
have an adverse effect on protein synthesis in rapidly growing tissues in young 
animals. 
6. In rats, a 28-day subchronic toxicity study was identified, with a NOAEL of 
854.3 mg/kg bw per day in males and 932.2 mg/kg bw per day in females. No 
adverse health effects were reported at the only dose tested. - The NOAEL in male 
rats corresponds to 59.8 g/day in a 70 kg human. 
For the risk characterisation of L-threonine, in the absence of long-term human studies in 
healthy individuals, VKM will base the value of comparison on the NOAEL demonstrated in a 
8-week randomised placebo controlled study in humans, that is 7500 mg corresponding to 
107 mg/kg bw per day.  
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3 Exposure / Intake 
Exposure of L-threonine was estimated from the intake of food supplements. For food 
supplements, the intake was estimated for the age groups 10 to <14 years, 14 to <18 years 
and adults (≥18 years). 
3.1 Food supplements 
The Norwegian Food Safety Authority requested VKM to perform a risk assessment of 1000, 
1200, 1500, 2000 and 2400 mg/day of L-threonine in food supplement for children (10 – 17 
years) and adults. The default body weights for age groups determined by EFSA were used: 
10 to <14 years = 43.4 kg, 14 to <18 years = 61.3 kg and adults = 70.0 kg. The exposures 
per kg bw are given in Table 3.1-1. 
Table 3.1-1 Estimated exposure of L-threonine from specified doses in food supplements in 
children, adolescents and adults. 
Groups Daily doses 
(mg) 
Body weight 
(kg) 
Exposures (mg/kg 
bw per day) 
Children (10 to <14 years) 1000, 1200, 
1500, 2000 and 
2400 
43 23, 28, 35, 46 and 55 
Adolescents (14 to <18 years) 1000, 1200, 
1500, 2000 and 
2400 
61 16, 20, 25, 33 and 39 
Adults (≥18 years) 1000, 1200, 
1500, 2000 and 
2400 
70 14, 17, 21, 29 and 34 
3.2 Other sources 
Threonine is an essential amino acid, with no endogenous synthesis. In the normal diet, the 
amino acids are ingested as components of food proteins and not as free acids. The 2007 
WHO recommendation is 15 mg/kg bw per day corresponding to 1050 mg/day for a 70-kg 
person. Deducing the amount of individual amino acids from soy bean protein, an intake of 
100 g protein, which is not an unusual intake for an adult European individual, would 
amount to an intake of 4 g threonine or 57 mg/kg bw per day for a 70-kg person. 
Based on NHANES III (1988-1994), the overall mean intake of L-threonine from food and 
food supplements in the United States was 3.0 g/day (43 mg/kg bw per day for a 70-kg 
person). Men aged 51-70 years had the highest intakes at the 99th percentile of 7.1 g/day 
(IOM, 2005). 
  
VKM Report 2017: 10  29 
4 Risk characterisation  
The doses received from NFSA for assessment were 1000, 1200, 1500, 2000 and 
2400 mg/day L-threonine in food supplements, and the estimated exposures for adults, 
adolescents and children 10 years and older derived from these dose levels are given in 
chapter 3.  
The value used for comparison with the estimated exposure in the risk characterisation is the 
NOAEL defined in a 8-week randomised placebo controlled study in humans, 7500 mg/day, 
with diary registration of adverse events. For a 70-kg individual, this corresponds to 107 
mg/kg bw per day.  
The NOAEL defined in a 4-week toxicity study in rodents, 854.3 mg/kg bw per day was 
based on the only dose tested, and a LOAEL has not been determined. 
Our literature review did not reveal any studies of threonine in children or adolescents, and 
there were no studies in children 10 years or older included in previous risk assessments. 
There are animal data suggesting that very young individuals are more vulnerable than 
adults for excessive doses of threonine, with reduced protein synthesis in fast-growing 
tissues as the adverse outcome. However, with an intake in the age groups considered in 
this risk evaluation in the form of supplements in amounts similar to or lower than what is 
obtained from food by adult individuals, it is considered to be unlikely that protein synthesis 
will be affected from the doses of threonine under evaluation. No tolerance level is therefore 
set for threonine specifically for children or adolescents. Assuming similar tolerance for these 
age groups as for adults, the same value for comparison as for adults is used for children 
and adolescents (107 mg/kg bw per day).  
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Table 4-1: The calculated margins between the highest dose tested in humans not associated with 
adverse effect (107 mg/kg bw per day) and the exposure to L-threonine from food supplements 
(MOE-values) for the various age groups. 
Age groups 1000 
mg/day 
1200 
mg/day 
1500 
mg/day 
2000 
mg/day 
2400 
mg/day 
Children (10 to 
14 years) 
(43.4 kg) 
5 4 3 2 2 
Adolescents (14 
to 18 years) 
(61.3 kg) 
7 4 3 3 3 
Adults (18 
years) 
(70 kg) 
7 6 5 4 3 
The calculated MOE-values for data from the human study ranged from 2 to 7 (Table 4-1) 
for a daily intake of 1000-2400 mg/day of L-threonine.  
MOE-values below 10 (for interindividual differences in humans) were regarded as 
acceptable since L-threonine is a nutrient that does not cause any known adverse health 
effects. In addition, the overall mean threonine intake according to NHANES III (3 g/day) is 
larger than the doses considered in the present risk assessment.  
VKM considers that: 
In adults (≥18 years), the specified doses 1000, 1200, 1500, 2000 and 2400 mg/day L-
threonine in food supplements are unlikely to cause adverse health effects.  
In adolescents (14 to <18 years), the specified doses 1000, 1200, 1500, 2000 and 
2400 mg/day L-threonine in food supplements are unlikely to cause adverse health effects.  
In children (10 to <14 years), the specified doses 1000, 1200, 1500, 2000 and 2400 mg/day 
L-threonine in food supplements are unlikely to cause adverse health effects. 
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5 Uncertainties 
 Long-term safety in healthy adults, adolescents and children has been extrapolated 
from shorter studies in adults  
 Toxicity in rodents according to OECD guidelines has been determined only in a one-
dose-level, four-week study in the rat (OECD Guideline 407) 
 Whether reduced protein synthesis with large intakes of threonine as observed in 
very young animals may be relevant for the youngest age group in our risk 
assessment 
 The human studies in our risk assessment include subjects suffering from multiple 
sclerosis, a condition supposed not to significantly affect threonine metabolism and 
the risk of adverse effects. However, a recent publication (Negrotto and Correale, 
2017) suggests that amino acid catabolism in multiple sclerosis may be decreased 
compared to what is observed in healthy individuals. The consequences, if any, for 
amino acid tolerance remain to be determined 
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6 Conclusions with answers to the 
terms of reference 
The Norwegian Food Safety Authority (NFSA) requested the Norwegian Scientific Committee 
for Food Safety (VKM) to assess the safety of L-threonine in food supplements at the doses 
1000, 1200, 1500, 2000 and 2400 mg/day for the general population, ages 10 years and 
above. The literature searches were conducted 5 April, 16 September and 13 October 2016, 
and included both human studies and animal studies.  
The literature search did not reveal any relevant studies in children (10 to <14 years) and 
adolescents (14 to <18 years). No data have been found indicating that children in this age 
group or adolescents are more vulnerable than adults for relevant doses of L-threonine and 
no tolerance level is set for L-threonine specifically for children or adolescents. The 
conclusions are therefore based on the assumption of similar tolerance for children and 
adolescents as for adults. 
Four human studies (two two-week studies, one eight-week study and a small one-year pilot 
study) and one four-week animal toxicity study are included in this report. For the risk 
characterisation of L-threonine, in the absence of long-term human studies in healthy 
individuals, VKM bases the value of comparison on the highest dose tested in one 8-week 
study in humans. The value of comparison is set to 107 mg/kg bw per day, corresponding to 
7500 mg/day in a 70 kg adult. The NOAEL determined in the four-week subchronic rat study 
supports the suggestion that these doses will be well tolerated in humans, and so do the two 
human two-week studies and the pilot study. MOE-values from 2 to 7 were regarded as 
acceptable since L-threonine is a nutrient that does not cause any known adverse health 
effects. In addition, the overall mean threonine intake according to NHANES III (3 g/day) is 
slightly larger than the doses considered in the present risk assessment. The requirement for 
threonine, 15 mg/kg bw/day, corresponding to– 1.1 g/day, is of similar magnitude as the 
doses considered in the present risk assessment.  
No particular vulnerable groups for L-threonine supplements have been identified. 
VKM concludes that: 
In adults (≥18 years), the specified doses 1000, 1200, 1500, 2000, and 2400 mg/day L-
threonine in food supplements are unlikely to cause adverse health effects.  
In adolescents (14 to <18 years), the specified doses 1000, 1200, 1500, 2000, and 2400 
mg/day L-threonine in food supplements are unlikely to cause adverse health effects. 
In children (10 to <14 years), the specified doses 1000, 1200, 1500, 2000, and 2400 mg/day 
L-threonine in food supplements are unlikely to cause adverse health effects.  
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An overview of the conclusions is presented in Table 6-1. 
Table 6-1: An overview of the conclusions for L-threonine in food supplements.  
Green: Estimated exposures to L-threonine are unlikely to cause adverse health effects. 
 
L-threonine 
Doses 
Age groups 
1000 
mg/day 
1200 
mg/day 
1500 
mg/day 
2000 
mg/day 
2400 
mg/day 
Children  
(10 to <14 years) 
       
Adolescents  
(14 to <18 years) 
       
Adults (≥18 years) 
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7 Data gaps 
 There is a lack of data from long-term human studies investigating potential adverse 
effects from L-threonine supplementation 
 No studies are found that include effects of threonine supplementation in lactating or 
pregnant women 
 No adequate animal studies on chronic toxicity, metabolic disturbances and 
carcinogenicity are available 
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Appendix 1 
Search strategies for this risk assessment 
Search strategy human studies 
Database: Embase <1974 to 2016 April 05>, Ovid MEDLINE(R) In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present> 
1. threonine*.ti. (9191) 
2. (risk* or safety or adverse or side-effect*1 or hazard* or harm* or negative or 
contraindicat* or 
3. contra-indicat* or interact* or toxicity or toxic).tw. (9789711) 
4. 1 and 2 (1781) 
5. (conference abstract* or letter* or editorial*).pt. (4934471) 
6. 3 not 4 (1709) 
7. limit 5 to (danish or english or norwegian or swedish) (1677) 
8. limit 6 to human (679) 
9. remove duplicates from 7 (427) 
Search strategy studies in children and adolescents 
Database: Embase <1974 to 2016 October 13>, Ovid MEDLINE(R) In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present> 
1. threonine*.ti. (9246) 
2. (child* or adolescent* or teenage* or college* or high school).tw. (3093526) 
3. 1 and 2 (24) 
4. limit 3 to (danish or english or norwegian or swedish) (23) 
5. remove duplicates from 4 (17) 
Search strategy animal studies 
Database: Embase <1974 to 2016 September 16>, Ovid MEDLINE(R) In-Process & Other 
Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present> 
1. threonine*.ti. (9359) 
2. (risk* or safety or adverse or side-effect*1 or hazard* or harm* or negative or 
contraindicat* or contra-indicat* or interact* or toxicity or toxic).tw. (10266610) 
3. 1 and 2 (1832) 
4. (conference abstract* or letter* or editorial*).pt. (5175652) 
5. 3 not 4 (1758) 
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6. limit 5 to (danish or english or norwegian or swedish) (1726) 
7. limit 6 to animals (609) 
8. remove duplicates from 7 (440) 
